University Of Leeds

The UK DANTE phase III trial found that 80.2% of patients who stopped immunotherapy after 12 months maintained disease control, compared to 87.6% who continued treatment for two years or more.

A phase 3 clinical trial led by the University of Leeds demonstrated that a second stem cell transplant followed by ixazomib maintenance therapy extends myeloma remission by seven months compared to standard care.

The phase 2 PLATO-ACT4 trial demonstrated that reduced-dose intensity-modulated radiotherapy (IMRT) achieved comparable complete clinical response rates to standard dosing in early-stage anal cancer patients.

Exploratory findings from the FOxTROT trial reveal that adding panitumumab to neoadjuvant FOLFOX chemotherapy significantly reduced recurrence and improved survival in patients with RAS/BRAF wild-type locally advanced colon cancer.

The second annual London Biotechnology Show (#LBS25) builds on the success of its inaugural edition, which attracted over 3,000 attendees from 1,500 companies and featured 70+ sponsors and exhibitors.